About this site
What Retatrutide Medicinal is — and what it isn't
An independent editorial project
Retatrutide Medicinal is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The domain name carries a medicinal framing — a positioning relative to the literature, not a claim about this site's services. There are no clinicians, no prescription pads, and no transactions here. What there is: a careful, cited reading of the retatrutide trial record, organized so that an attentive non-specialist can follow it.
Why this site exists
Retatrutide generated significant public interest after its Phase 2 obesity trial published in the New England Journal of Medicine in 2023, showing up to −24.2% body weight reduction in a 48-week randomized controlled trial. Since then, a large amount of poorly sourced, uncited, and sometimes inaccurate information about retatrutide has circulated online — mixing clinical trial findings, gray-market vendor claims, and community anecdote without clear labels for which is which.
This site attempts to do the opposite: distinguish what the trials showed (cited, attributed, specific) from what the research-use community reports (labeled explicitly as anecdotal, not clinical evidence), and from what is simply unknown. That structure is the core editorial commitment of this project.
What we cover and what we don't
This site covers the peer-reviewed clinical trial record for retatrutide — Phase 1b first-in-human pharmacokinetics, Phase 2 obesity, Phase 2 type 2 diabetes, Phase 2 liver disease, structural pharmacology, and 2025–2026 publications on appetite, eating behavior, and emerging safety signals. It also covers, with explicit labels, what research-use communities report based on publicly available forum discussions.
This site does not cover: where to obtain retatrutide, how to dose it outside a clinical trial, reconstitution or preparation instructions, comparative vendor analysis, or anything in the commercial supply chain. It does not provide individualized guidance of any kind. Questions that are medical in nature — particularly questions from people currently managing type 2 diabetes, obesity, or cardiovascular disease with medications — belong with a licensed clinician, not an editorial digest.
About the editorial approach
Every quantitative claim on this site is cited to a specific study. Citations appear as [N] in the text and link to the full reference in Retatrutide references. The site distinguishes four types of information: clinical trial findings (attributed to a specific trial with a specific population), structural/mechanistic pharmacology (attributed to in vitro or structural studies), community-reported effects (labeled explicitly as anecdotal, not clinical evidence), and ongoing/unknown (for questions the completed trials have not answered).
The site is updated to reflect significant new publications in the retatrutide record. It does not carry advertising. It does not have a commercial relationship with Eli Lilly or any other pharmaceutical company, research vendor, or clinical service.